Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 6, 1996 - Issue 5
Submit an article Journal homepage
6
Views
4
CrossRef citations to date
0
Altmetric
Research

Section Review Central & Peripheral Nervous Systems: Recent developments in the treatment of encephalomyelitis

Xia Liu Georgetown University, Departments of Neurosurgery and Pharmacology, Research Building W208, 3970 Reservoir Road, Washington, DC, 20007, USA
,
George A Mashour Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA
&
Andreas Kurtz Georgetown University, Departments of Neurosurgery and Pharmacology, Research Building W208, 3970 Reservoir Road, Washington, DC, 20007, USA
Pages 457-470 | Published online: 29 Feb 2008

References to Primary Literature

  • HLA and disease associations. Springer Verlag, New York (1985) 152 pp.
  • THE IDNB MULTIPLE SCLEROSIS STUDY GROUP AND THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP. Interferon beta-113 in the treatment of multiple sclerosis; final outcome of the randomised controlled trial. Neurology (1995) 45:1277–1285.
  • AHARONI R, TEITELBAUM D, ARNON R, PURI J: Immuno-modulation of experimental allergic encephalomyelitis by antibodies to the antigen-Ia complex. Nature 351:147–150.
  • ARHELOS JJ, JUNG S, MAURER M, SCHMIED M, LASSANNH, TAATANI T, MIYASAKA M, TOYKA VK, HARTUNG HP: Inhibition of experimental autoimmune encephalo-myelitis by an antibody to the intercellular adhesion molecule ICA-1. Ann. Neurol. 34:145–154.
  • ARMSTRONG RC, DORN HH, KUFTA CV, FRIEDMAN E,DUBOIS-DALCQ ME: Pre-oligodendrocytes from adult human CNS. J. Neurosci. (1992) 12:1538–1547.
  • ARNASON BG: Interferon beta in multiple sclerosis. Neurology (1993) 43:641-643 ieditorial; comment].
  • BAR RS, BOES M, DAKE BL, BOOTH BA, HENLEY SA, SANDRA A: Insulin, insulin-like growth factors and vascular endothelium. Am. J. Med. (1988) 5:59–70.
  • BAR RS, BOTH BA, BOES, BAKE BL: Insulin-like growth factor-binding proteins from vascular endothelial cells: puffication, characterisation and intrinsic biological activities. Endocrinology (1989) 125:1910–1920.
  • BEALL SS, BIDDISON WE, MCFARLIN DE, MCFARLAND HF,HOOD LE: Susceptibility for multiple sclerosis is deter-mined, in part, by inheritance of a 175-kb region of the Tell V beta chain locus and HLA class II genes. J. Neuroimmunol. (1993) 45:53–60.
  • BECK J, RONDOT P, JULLIEN P, WIETZERBVIN J, LAWRENCE DA: TGF-beta-like activity produced during regression of exacerbations in multiple sderosis. Acta. Neurol. Scand. (1991) 84:452–455.
  • BECK KD, POWELL-BRAXTON L, WIDER HR, VALVERDE J, HEFTI F: Igfl gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. Neuron (1995) 14:717–730.
  • BESNARD F, PERRAUD F, SENSENBRENNER M, LABOUR-DE 11 E G: Effects of acidic and basic gibroblast growth factors on proliferation and maturation of cultures rat ologodendrocytes. Int.J. Dev. Neurosci. (1989) 7:401–409.
  • BIDDISON WE, BEALL SS, CONCANNON P, CHARLEY P, GATTI RA, HOOD LE, MCFARLAND HF, MCFARLIN DE: The germline repertoire of T-cell receptor beta-chain genes In patients with multiple sclerosis. Res. Immunol. (1989) 140:212–218.
  • BROCKE MS, GIJBELS K, ALLAGRETTA AM, FERBER I, PIERCY C, BLANKENSTEIN T, MARTIN R, UTZ U, KARIN N, MITCHELL D, VEROOMA T, WAISAN A, GAUR A, CONLONP, LING N, FAIRCHILD PJ, WRAITH DC, O'FARRA A, PATHAN CG, STEINMAN L: Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature (1996) 379:343–346.
  • BROD SA, KHAN M, KERMAN RH, PAPPOLLA : Oral ad-ministration of human or murine interferon alpha suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis. J. Neuroimmunol. (1995) 58:61–69.
  • BROSTODD SW, MASON DW: Experimental allergic en-cephalomyelitis successful treatment in vivo with a monoclonal antibody that recognises T helper cells. J. Immunol. (1984) 133:1938–1942.
  • CANNELLA B, CROSS AH, RAINE CS: Anti-adhesion mole-cule therapy in experimental autoimmune encephalo-myelitis. J. Neuroimunol. (1993) 46:43–55.
  • CANNELLA B, RAINE CS: The adhesion molecule and ctyokine profile of multiple sderosis lesions. Ann. Neurol. (1995) 37:4424-4435 [see comments].
  • CARSON MJ, BEGRINGER RR, BRINSTER RI, MCMORRIS FA: Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice. Neuron. (1993) 10:729–740.
  • CHAMORRO M, AUBERT C, BRAHIC M: Demyelinating lesions due to Theiler's virus are associated with ongo-ing central nervous system infection. J. Virol. (1986) 57:992–997.
  • CLATCH RJ, KlPTON L, MILLER SD: Characterisation ofTheiler's murine encephalomyelitis virus (TMEV)-spe-cific delayed-type hypersensitivity responses in TMEV-induced demyelinating disease: correlation with clinical signs. J. Immunol. (1986) 136:920–927.
  • COMPSTON A: Future prospects for the management ofmultiple sclerosis. Ann. Neurol. (1994) 36:S146-S150 (suppl.).
  • CRTTCHFIELD JM, RACKE MK, ZUNIGA-PFLUCKER JC, CAN-NELLA B, RAINE CS, GOVERAN J, LENARDO MJ: T cell deletion in high antigen dose therapy of autoin:unune encephalomyelitis. Science (1994) 263:1139–1143.
  • DAL CANTO MC, LIPTON HL: Multiple sclerosis. Animal model: Thaler's virus infection in mice. A. J. Pathol. (1977) 88:497–500.
  • DAWSON T, DAWSON VL, SNYDER Sti: A novel neuronalmessenger molecule in brain: the free radical, nitric oxide. Ann. Neurol. (1992) 32:297-311 [see comments].
  • DURELL1 L, BONGIOANNI ME, CAVALLO R, FERRERO B, FERRI R, FERRI° ME, BRADAC GB, RIVA A, VAT MS, GEUNAM et al.: Chronic systemic high-dose recombinant inter-feron alpha-2a reduces exacerbation rate, Mill signs of disease activity, and lymphocyte interferon gama pro-duction in relapsing-remitting Multiple Sclerosis. Neurology (1994) 44:406–413.
  • EVERS GC, BULMAN DE, SADOVNICK AD, PATY DW, WARREN MS, HADER W, MURRAY TJ, SELAND TP DUQUEI iF. P, GREY T et al.: A population-based study of multiple sclerosis in twins. N. Engl. J. Med. (1986) 315:1638–1642.
  • ECCLESTON PA, SELBERBERG DH: Fibroblast growth fac-tor is a mitogen for oligodendrocytes in vitro. Brain Res. (1985) 353:315–318.
  • FRITZ RB, MCFARLIN DE: Encephalitogenic epitopes ofmyelin basic protein. In: Antigenic determinants and immune response. EE Sercarz, (Ed.) Hager, Basel (1989) 101–125.
  • FUJITA N, SATO MS, KURIHARA T, KUWANO R, SAKIMURAK, INUZUKDA T, TAKAHASHI Y, IYATAKE T: CDNA don-ing of mouse myelin-associated glycoprotein: a novel alternative splicing pattern. Biochem. Biophys, Res. Com-mun. (1989) 165:1162–1169.
  • GAUR A, RUBERTI G, HASPEL R, MAYER JP, FATIIMAN CG:Requirement for CDS+ cells in T cell receptor peptide-induced clonal unresponsiveness. Science 259:91-94 [published erratum appears in Science (1993) Apr 16; 260(5106):preceding 2811.
  • GORODEZKY C, NAJERA R, RANGEL BE, CASTRO LE, FLORES J, VELAZQUEZ G, GRANADOS J, SOTELO J: Imu-nogenetic profile of multiple sclerosis in Mexicans. Hum. Imunol. (1986) 16:364–374.
  • GOVERNMAN J, WOODS A, LARSON L, WEINER LP, HOODL, ZALLER DM: Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontane-ous autoimmunity. Cell (1993) 72:551–560.
  • GRINSPAN JB, STERN J, FRANCESCHINI B, YASUDA T,PLEASURE D: Protein growth factors as potential thera-pies for central nervous system demyelinative disor-ders. Ann. Neurol. (1994) 36:S140-S142 (suppl.).
  • GRINSPAN JB, STERN JL, FRANCESCHINI B, PLEASURE D: Trophic effects of basic fibroblast growth factor (bFGF) on differentiated ollgodendroglia: a mechansim for regeneration of the oligodendroglial lineage. J. Neurosci. Res. (1993) 36:672–680.
  • GRINSPAN JB, STERN JL, PUSTILNIK SM, PLEASURE D: Cerebral white matter contains PDGF-responsive pre-cursors to 02A cells.]. Neurosci. (1990) 10:1866–1873.
  • HARTUNG HP: Immune-mediated demyelination. Ann.Neurol. (1993) 33:563-567 [comment].
  • NARTUNG HP, HIUGHES RA, TAYLOR WA, I TEININGER K, REINERS K, TOYKA KV: T cell activation in Guillain-Barre syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology (1990).
  • HAUSER SL; Prevention strategies for multiple sclerosis. Ann. Neurol. (1994) 36:S157-S162 (suppl.).
  • HEBER-KATZ E, ACHA-ORBEA H: The V-region disease hypothesis: evidence from autohnmune encephalo-myelitis. Immunol. Today (1989) 10:164–169.
  • HOWELL MD, WINTER ST, OLEE T, POWELL HC, CAROLDJ, BROSTOFF SW: Vaccination against experimental allergic encephalomyelitis with T cell receptor pep-tides. Science 246:668-670 [published erratum appears in Science (1990) Mar 9 247(4947):11671.
  • JACOBS CA, BAKER PE, ROUX ER, PICI IA KS, TOIVOLA B,WAUGH MS, KENNEDY MK: Experimental autoimune encephalomyelitis is exacerbated by 11-1 alpha and suppressed by soluble 11-1 receptor. J. Immunol. (1991) 146:2983–2989.
  • JACOBS L, JOHNSON KP: A brief history of the use ofinterferons as treatment of multiple sclerosis. Arch Neurol. (1994) 51:1245–1252.
  • JACOBSON M, GUPTA A, ATTSON D, MINGIOLI E, McFAR-LIN DE: Immunological studies in tropical spastic para-paresis. Ann. Neurol. (1990) 27:149–156.
  • JOHNS LD, FLANDERS KC, RANGES GE, SRLRA M: Successful treatment of experimental allergic encephalomyeli-tis with transforming growth factor-beta 1. J. Immunol. (1991) 147:1792–1796.
  • THE COPOLYMER 1 MULTIPLE SCLEROSIS STUDY GROUP:JOHNSON KP, BROODS BR, COHEN JHA, FORD CC, GOLD-STEIN J, LISAK RP, YERS LW, PANITCH HS, ROSE JW, SCHIFFER RB et al.: Copolymer 1 reduces relapse rate and improved disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trials. Neurology (1995) 45:1268-1276 [see comments].
  • JOHNSON RT: Viral aspects of multiple sclerosis. In:Handbook of clinical neurology. Demyelinating diseases. Vinken, PJ, Bruyn GW & Klawans HL (Eds.) Elsevier Science Publishers, Amsterdam/New York. (1985) 319–336.
  • KAMHOLZ J, DE FERRA F, PUCKETT C, LAZZARINI R: Identification of three forms of human myelin basic protein by cDNA cloning. Proc. Natl. Acad. Sci. USA (1986) 83:4962–4966.
  • KAMHOLZ J, TOFFENETTI J, LAZZARINI RA: Organisation and expression of the human myelin basic protein gene. J. Neurosci. Res, (1988) 21:62–70.
  • KAPPLER J, KOTZIN B, HERRON L, GELFAND EW, BIGLER RD, BLYLSTON A, CARREL S, POSNETT DN, CHOR Y, ARRACK P: V beta-specific stimulation of human T cells by staphylococcal toxins. Science (1989) 244:811–813.
  • KARUSSIS DM, LEHANN D, SLAVIN MS, VOURKA-KARUSSIS U, IZRACHI-KOLL R, OVADIA H, KALLAND T, ABRAMSKY 0: Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic ina-munomodulator linoide (quinoline-3-carboxamide). Proc. Natl. Acad. Sci. USA (1993) 90:6400–6404.
  • KOMOLY S, HUDSON LD, WEBSTER HD, BONDY CA: Insulin-like growth factor I gene expression is induced In astrocytes during experimental demyelination_ Proc. Natl. Acad. Sci. USA (1992) 89:1894–1898.
  • KOPROWSK1 H, TER MEULEN V: Multiple sclerosis andparainfluenza 1 virus. History of the isolation of the virus and expression of phenotypic differences be-tween the isolated virus and Sendai virus. J. Neurol. (1975) 208:175–190.
  • KURDI A, AYESH I, ABDALLAT A, MAAYTA U: Different Blymphocyte alloantigens associated with multiple scle-rosis in Arabs and North Europeans. Lancet (1997) 1:1123–1125.
  • KURLAND LT: The evolution of multiple sclerosis epide-mology. Ann. Neurol. (1994) 36:S2-S5 (suppl.).
  • LAMONT AG, SE! I bR A, FUJINAMI R, COLON SM, ILES C,GREY H: Inhibition of experimental autoimmune en-cephalomyelitis induction in SJL/J mice by using a peptide with high affinity for lAs molecule. J. Immunol. (1990) 145:1687–1693.
  • LASSMANN H, SUCHANEK G, OZAWA K: Histopathology and the blood-cerebrospinal fluid barrier in Multiple Sclerosis. Ann. Neurol. (1994) 36:S42-S46 (suppl.).
  • LENARDO MG: Interleukin-2 programs mouse alpha beta T lymphocytes for apoptos is. Nature (1991) 353:858–861
  • EIDER 0, SANTOS LM, LEE CS, HIGGINS PJ, EINER HL: Suppression of experimental autoinarnune encephalo- myelitis by oral administration of myelin basic protein. II. Suppression of disease and in vitro immune re-sponses is mediated by antigen-specific CDS+ T lym-phocytes. J. Immunol. (1989) 142:748–752.
  • LIPTON HL, DAL CANTO MC: Theikr's virus-induced demyelination: prevention by immunosuppression. Science (1976) 192:62–64.
  • LIU X, YAO DL, 'WEBSTER H DE F: Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelination experimental autoim-mune encephalomyelitis. Multiple Sclerosis (1995) 5:418–430.
  • LID X, YAO DL, BONDY CA, BRENNER, HUDSON LD, ZHOU J & WEBSTER HD: Astrocytes express insulin-like growth factor-I (IGF-I) and its binding protein, IGFBP-2, during demyelination induced by experimental autoimmune encephalomyelitis. Mol l. Cell Neurosci. (1994) 5:418–430.
  • MARROSU MG, MUNTONI F, MURRU MR, SPINICCI G, PISCHEDDA MP, GODDI F, COSSU P, PIRATSU M: Sardin-ian multiple sclerosis is associated with ifLik-DR4: a serologic and molecular analysis. Neurology (1988) 38: 1749-1753.
  • MARTIN JR: Herpes simplex virus types 1 and 2 andmultiple sclerosis. Lancet (1981) 2:777–781.
  • MARTIN R, MCFARLAND HE Immunological aspects of experimental allergic encephalomyelitis and Multiple Sclerosis. Crit. Rev. Clin. Lab. Sci. (1995) 32:121–182.
  • MATHEWS LS, HAMER RE, BEHRINGER RR, D'ERCOLE AJ, BELL GI BRINSTER RL, PALMITER RD: Growth enhance-ment of transgenic mice expressing human insulin-like growth factor L Endocrinology (1988) 123:2827–2833.
  • MCFARLIN DE: Neurological disorders related to HTLV-I and HTLV-II. J. Acquir. Immune Defic. Syndr. (1993) 6:640–644.
  • MCKINNON RD, MATSUI T, DUBOIS-DALCQ M, AARON-SON SA: FGF modulates the PDGF-driven pathway of oligodendrocyte development. Neuron (1990) 5:603–614.
  • MCMORRIS RA, SMITH TM, DE SALVO S, FURLANETTO RW: Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte development. Proc. Natl. Acad. Sci. USA (1986) 83:822–826.
  • METZLER B, WRAITH DC: Inhibition of experimentalautoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: Influence of MHC binding affinity. Int. Immunol. (1993) 5:1159–1165.
  • MOKHTARIAN FD, MCFARLIN DE, RAINE CS: Adoptive transfer of myelin basic protein-sensitised T cells pro-duces chronic relapsing demyelinating disease in mice. Nature (1984) 309:356–358.
  • NAITO S, KUROIWA Y, ITOYAMA T, TSUBAK/ T, HORIKAWA A, SASAZUKI T, NOGUCHI MS, OHTSUKI S, TOKUOMI H, MIYATAKE T, TAKAHATA N, KAWANAMI S: HLA and Japanese MS. Tissue Antigens (1978) 12:19–24.
  • NORONHA A, TOSCAS A, JENSEN MA: Interferon betadecreases T cell activation and interferon gamma pro-duction in multiple sclerosis. J. Neuroimmunol. (1993) 46:145–153.
  • OKSENBERG JR, SHERRITT M, BEGOVICH AB, ERLICH HA,BERNARD CC, VAVALLI-SFORZA LL, STEINMAN L: T cell receptor V alpha and C alpha alleles associated with multiple and myasthenia gravis. Proc. Natl. Acad. Sci. USA. (1989) 86:988–992.
  • OLDSTONE MBA, NOTKINS AL: Molecular mimicry. In:Concepts in viral pathogenesis. Oldstone MBA, (Ed.) Springer Verlag, New York. (1986) 195–202.
  • OSAME M, MATSUMOTO M, USUKU K, IZUMO S, IJICHI N,AMITANT H, TARA M, IGATA A: Chronic progressive myelopathy associated with elevated antibodies to hu-man T-lymphotropic virus type I and adult T cell leu-kaemia-like cells. Ann. Neurol. (1987) 21:117–122.
  • PANITCH HS: Influence of infection on exacerbations of Multiple Sclerosis. Ann. Neurol. (1994)36:S25-S28 (suppl.).
  • PARDRIDGE WM: Transport of insulin-related peptides and glucose across the blood-brain barrier. Ann. NY Acad. Sci. (1993) 692:126–137.
  • PELFREY CM, TRANQUILL LR, BOEBEE SA, McFARLAND HF, LENARDO MJ: Two mechanisms of antigen-specific apoptosis of myelin basic protein (MBP)-specific T lymphocytes derived from multiple sclerosis patients and normal individuals. J. Immunot (1995) 154:6191–6202.
  • RACKE MK, BONOMO A, SCOTT DE, CANNELLA B, LEVINE A, RAINE CS, SHEVACH EM, ROCKEN M: Cytokine-induced Immune deviation as a therapy for inflammatory autoinimune disease. J. Exp. Med. (1994) 180:1961–1966.
  • RACKE MK, DHIB-JALBUT S, CANNELLA B, ALBET PS, RAINE CS, MCFARIIN DE: Prevention and treatment of chronic relapsing experimental allergic encephalo-myelitis by transforming growth factor-beta 1.J. Immu-nol. (1991) 146:3012–3017.
  • RACKE K, MARTIN R, MCFARLAND, FRITZ RB: Copolymer-
  • -induced inhibition of antigen-specific T cell activa-tion: interference with antigen presentation. J. Neunoimmunol. (1992) 37:75–84.
  • RAINE CS: The Dale E McFarlin Memorial Lecture: the Immunology of the Multiple Sclerosis lesion. Ann. Neurol. 36:S61-S72 (suppl.).
  • RAINE CS, MOKIITARIAN F, McFARLIN DE: Adoptively transferred chronic relapsing experimental autoim-mune encephalomyelitis in the mouse. Neuropathologic analysis. Lab. Invest. (1984) 51:534–546.
  • RICHARDSON WD, PRINGLE N, MOSLEY MJ, WESTERMARK B, DUBOIS-DALCQ M: A role for platelet-derived growth factor in normal g,liogenesis in the central nervous system. Cell (1988) 53:309–319.
  • RODER J, KICKEY WF: Mouse models, immunology, multiple sclerosis and myelination. Nature Genetics (1996) 12:6–8.
  • ROSENFELD RG, PHAM H, 10ELLER BT, BORCHARDT RT, PARDRIDGE WM: Demonstration and structural com-parison of receptors for insulin-like growth factor-I and -11 (IGF-I and -II) in brain and blood-brain barrier. Biocbem. Bioploys. Res. Commun. (1987) 149:159–166.
  • SADOVNICK AD, EBERS GC: Genetics of multiple sclero-sis. Neural. Clin. (1995) 12:99–118.
  • SAKAI K, ZAMVIL SS,MITCHELL DJ, HODGKINSON S, ROTHBARD JB, STEINMAN L: Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex pro-teins. Proc. Natl. Acad. Sci. USA (1989) 86:9470–9474.
  • SEBOUN E, ROBINSON MA, DOOLITTLE TH, CIULLA TA,KINDT TJ, HAUSER SL: A susceptibility locus for multiple sclerosis is linked to the T cell receptor beta chain complex. Cell (1989) 57:1095–1100.
  • SECKINGER P, ISAAZ S, KAYER JNI: A human inhibitor oftumour necrosis factor alpha. J. Exp. Med. (1988) 167:1511–1516.
  • SELMAJ K, RAINE CS: Tumour necrosis factor mediatesmyelin damage on organotypic cultures of nervous tissue. Ann. NY Acad. Sci. (1988) 540:568–570.
  • SELAJ DW, RAINE CS, FAROOQ M, NORTON WT, BROSNANCF: Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin. J. lmmunol. (1991) 147:1522–1529.
  • SELMAJ KW, RAINE CS: Tumour necrosis factor mediatesmyelin and oligodendrocyte damage in vitro. Ann. Neurol. (1988) 23:339–346.
  • SELMAJ KW, RAINE CS: Experimental autoimune en-cephalomyelitis: imunotherapy with anti-tumour ne-crosis factor antibodies and soluble tumour necrosis factor receptors. Neurology (1995) 45:S44–S49.
  • SHARIEF MK, HENTGES R: Association between tumournecrosis factor-alpha and disease progression in pa-tients with multiple sclerosis. N. Engl, J. Med. (1991) 325:467-472 [see comments].
  • SHARIEF MK, THOPSON Ej: Correlation of interleukin-2and solluble interleukin-2 receptor with clinical activity of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. (1993) 56:169–174.
  • SIPE JC, ROMINE JS, KOXIOL JA, MCMILLAN R, ZYROFF J, BEUTLER E: Cladribine in treatment of chronic progres-sive multiple sclerosis. Lancet (1994) 344:9–13.
  • TEITELBAUM D, AHARONI R, ARNON R, SELA M: Specific inhibition of the T cell response to myelin basic protein by the synthetic copolymer Cop 1. Proc. Natl. Acad. Sci. USA (1988) 85:9724–9728.
  • TSLRICA SE, GUALANDRIS A, AMARAL DG, STRICKLAND 5: Excitotoxin-induced neuronal degeneration and sei-zure are mediated by tissue plasminogen activator. Nature (1995) 377:340–344.
  • URBAN JL, HORVATH SJ, HOOD L: Autoimmune T cells: Immune recognition of normal and variant peptide epitopes and peptide-based therapy [retracted by Hood L, Urban JL, Horvath SJ. In: Cell (1991) Jan 25; 64(2):231–21. Cell 59:257–271.
  • URBAN JL, KUMAR V, KONO DK GOMEZ C, HORVATH SJ, CLAYTON J, ANDO DG, SERCARZ EE, HOOD L: Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy. Cell (1988) 54:577–592.
  • VANDENBARK AA, HASHIM G, OFFNER H: Immunisation with a synthetic T cell receptor V-region peptide pro-tects against experimental autoinimune encephalo-myelitis. Nature (1989) 341:541–544.
  • WALDOR MK, SRIRAM S, HARDY R, HERZENBERG LA, LANIER L, LIM M, STEINMAN L: Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T cell subset marker. Science (1985) 227:415–417.
  • WHITAKER JN: Rationale for immunotherapy in multi-ple sclerosis. Ann. Neurol. (1994) 36:S103-S107 (suppl.).
  • WOOD P, BUNGE RP: The origin of remyelinating cells In the adult central nervous systme: the role of the mature oligodendrocyte. Glia. (1991) 4:225–232,
  • WOODROOFE MN, HAYES GM, CUZNER ML. Fc receptor density, MHC antigen expression and superoxide pro-duction are increased in interferon-gamma-treated mi-croglia isolated from adult rat brain. Immunology(1989) 68:421–426.
  • WRAITH DC, SMILEK DE, MITCHELL DJ, STEINMAN L, MCDEVITT HO: Antigen recognition in autoirnmune encephalomyelitis and the potential for peptide-medi-ated immunotherapy. Cell (1989) 59:247–255,
  • YAO DL, LIU X, HUDSON LD, WEBSTER HD: Insulin-like growth factor I treatment reduces demyelination and up-regulates gene expression of myelin-related pro-teins in experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA. (1995) 92:6190–6194.
  • YAO DL, WEST NR, BONDY CA, BRENNER M, HUDSON LD, ZHOU J, COLLINS GH, WEBSTER HD: Cryogenic spinal cord unjury induces astrocytic gene expression of in-sulin-like growth factor land insulin-like growth factor binding protein 2 during myelin regeneration. J. Neuro-sci. Res. (1995) 40:647–659.
  • ZAMVIL S, NELSON P, TROTTER J, MITCHELL D, KNOBLER R, FRITZ R, STEINMAN L: T cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature (1985) 317:355–358.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.